• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Therapeutic strategy based on the direct degradation of disease-related proteins

Research Project

Project/Area Number 18K06570
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 47010:Pharmaceutical chemistry and drug development sciences-related
Research InstitutionThe University of Tokyo

Principal Investigator

Yachide Tomomi  東京大学, 定量生命科学研究所, 准教授 (20401284)

Project Period (FY) 2018-04-01 – 2021-03-31
Project Status Completed (Fiscal Year 2020)
Budget Amount *help
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2020: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Keywords核内受容体 / エピジェネティクス / 構造展開 / 構造活性相関 / タンパク質分解誘導 / エストロゲン受容体 / ブロモドメイン / 医薬品探索 / SERD / 転写因子 / 分解誘導 / 薬学 / 創薬化学
Outline of Final Research Achievements

I carried out research on the development of novel pharmacological agents for the treatment of endocrine-resistant breast cancer, for which no clear therapeutic strategy has been established. As a result, I developed pharmaceutical lead compounds that directly degrades disease-related proteins. Specifically, I selected estrogen receptor, which has been reported to be involved in these diseases, and bromodomain (BRD), which is the epigenetic regulator and attracting attention as a candidate therapeutic target for cancer, and developed compounds that induce the degradation of these proteins (selective estrogen receptor down-regulators and BRD degradation inducers). By analyzing the mechanism of action of the discovered compounds and their effects on downstream signaling, I have developed them into compounds that can truly serve as pharmaceutical leads.

Academic Significance and Societal Importance of the Research Achievements

乳がんは、食の欧米化や妊娠回数の減少(女性ホルモン暴露期間の延長)に伴い、増加傾向にある。一方、閉経後乳がんやトリプルネガティブ乳がんといった、ホルモン療法耐性乳がんの当該所望化合物の創製・治療戦略は未だ確立していない。タンパクの寿命を制御する医薬は新たな治療戦略として期待されているが、その医薬化学的・生化学的情報は欠如している上、ファーマコフォアも限定されている。このような背景より、従来のホルモン療法と概念を異にする治療戦略の確立が求められている。本研究により、ホルモン療法耐性乳がん治療薬創製を目指した今後の『戦略的な基礎創薬化学研究』に革新的な方向性と学術基盤を付与することが可能である。

Report

(4 results)
  • 2020 Annual Research Report   Final Research Report ( PDF )
  • 2019 Research-status Report
  • 2018 Research-status Report
  • Research Products

    (9 results)

All 2019 2018 Other

All Journal Article (3 results) (of which Peer Reviewed: 3 results) Presentation (4 results) (of which Int'l Joint Research: 2 results,  Invited: 1 results) Book (1 results) Remarks (1 results)

  • [Journal Article] Structure-activity relationship study of estrogen receptor down-regulators with a diphenylmethane skeleton2019

    • Author(s)
      Nanjyo Shun、Ohgane Kenji、Yoshioka Hiromasa、Makishima Makoto、Hashimoto Yuichi、Noguchi- Yachide Tomomi
    • Journal Title

      Bioorganic & Medicinal Chemistry

      Volume: 27 Issue: 10 Pages: 1952-1961

    • DOI

      10.1016/j.bmc.2019.03.042

    • Related Report
      2019 Research-status Report
    • Peer Reviewed
  • [Journal Article] Design and synthesis of estrogen receptor ligands with a 4-heterocycle-4-phenylheptane skeleton2018

    • Author(s)
      Eto Ryo、Misawa Takashi、Noguchi-Yachide Tomomi、Ohoka Nobumichi、Kurihara Masaaki、Naito Mikihiko、Tanaka Masakazu、Demizu Yosuke
    • Journal Title

      Bioorganic & Medicinal Chemistry

      Volume: 26 Issue: 8 Pages: 1638-1642

    • DOI

      10.1016/j.bmc.2018.02.010

    • Related Report
      2018 Research-status Report
    • Peer Reviewed
  • [Journal Article] Unexpected Emergence of Luciferase-Inhibitory Activity During Structural Development Study of Phenyloxadiazole-based Ppar Ligands2018

    • Author(s)
      Ryuta Shioi, Yosuke Toyota, Tomomi Noguchi-Yachide, Minoru Ishikawa, Takao Yamaguchi, Makoto Makishima, Yuichi Hashimoto, and Kenji Ohgane
    • Journal Title

      HETEROCYCLES

      Volume: 97 Issue: 2 Pages: 854-864

    • DOI

      10.3987/com-18-s(t)61

    • Related Report
      2018 Research-status Report
    • Peer Reviewed
  • [Presentation] Development of bioactive compounds based on bis-aryl (6-X-Y-6) skeleton.2019

    • Author(s)
      T. Noguchi-Yachide, K. Ohgane, Y. Hashimoto
    • Organizer
      BIOHETEROCYCLES 2019
    • Related Report
      2019 Research-status Report
    • Int'l Joint Research
  • [Presentation] 薬の研究って何だろう?2019

    • Author(s)
      谷内出友美
    • Organizer
      かながわリケジョ・エンカレッジプログラム(かながわ女性の活躍応援団啓発講座)
    • Related Report
      2019 Research-status Report
    • Invited
  • [Presentation] Development of dual BRD4/HDAC inhibitors2018

    • Author(s)
      Tomomi Noguchi-Yachide, Seika Amemiya, Takao Yamaguchi, Yuichi Hashimoto
    • Organizer
      RICT2018
    • Related Report
      2018 Research-status Report
    • Int'l Joint Research
  • [Presentation] ERダウンレギュレーターの構造活性相関研究2018

    • Author(s)
      谷内出友美、南條舜、大金賢司、橋本祐一
    • Organizer
      レチノイド研究会学術集会
    • Related Report
      2018 Research-status Report
  • [Book] Pharmacoepigenetics -Translation Epigenetics Series- Volume 102019

    • Author(s)
      Tomomi Noguchi-Yachide(edited by Ramon Cacabelos)
    • Total Pages
      11
    • Publisher
      Academic Press
    • ISBN
      9780128139394
    • Related Report
      2019 Research-status Report
  • [Remarks] 東京大学定量生命科学研究所生体有機化学研究分野

    • URL

      http://www.iam.u-tokyo.ac.jp/chem/IMCB-8ken-HP/Index.html

    • Related Report
      2019 Research-status Report 2018 Research-status Report

URL: 

Published: 2018-04-23   Modified: 2022-01-27  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi